FINWIRES · TerminalLIVE
FINWIRES

RBCによると、アメリカのヘルスケアREITは投資ペースの加速から恩恵を受ける見込み。

-- RBCキャピタル・マーケッツは月曜日に電子メールで送付したレポートの中で、アメリカン・ヘルスケアREIT(AHR)の2026年FFO(運用資金)予想を、同社の第1四半期決算発表を前に上方修正した。これは、投資ペースの加速が業績に好影響を与えるとの見方に基づいている。 RBCのレポートによると、アメリカン・ヘルスケアREITの2026年FFO予想は1株当たり2.04ドルとなり、前期比0.03ドルの上昇となる。これは、経営陣が示していた1株当たり1.99ドル~2.05ドルの見通し範囲を上回るものだ。 RBCは、この新たな予想は同社の投資ペースの加速に裏付けられているとし、年間約9億ドルの純投資活動が、RBCの以前の予想と比べて約3億5000万ドル増加していることを示している。 しかしながら、RBCは、この成長はトリロジーの既存店舗純営業利益(NOI)の伸びが「より緩やか」になることで相殺される可能性が高いと指摘した。2026年と2027年の年平均成長率は10%と予測されており、これはRBCの以前の予測値から約200ベーシスポイント低下する。 新たな予測では、今年のコア利益成長率は18.5%、来年は15.9%と見込まれており、この見通しは「概ね、レバレッジを効かせた低二桁台のオーガニック成長と中一桁台の外部成長に支えられているが、一般管理費やその他の費用の流出が緩やかに相殺されている」とレポートは述べている。 アメリカン・ヘルスケアREITは5月7日に第1四半期決算を発表する予定である。 RBCはアメリカン・ヘルスケアREITの投資判断を「アウトパフォーム」、目標株価を54ドルに据え置いた。

Price: $48.38, Change: $-0.85, Percent Change: -1.73%

Related Articles

Research

Research Alert: CFRA Keeps Buy Opinion On Shares Of The Hartford Insurance Group, Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We trim our 12-month target price by $8 to $155, valuing HIG shares at 11.3x our 2026 operating EPS estimate of $13.75 (cut by $0.45) and at 10.6x our 2027 EPS estimate of $14.65 (cut by $0.30), vs. the shares' one-year average forward multiple of 10.3x and peer average of 13x. Q1 EPS of $3.09 vs. $2.20 a year ago missed our $3.60 estimate and $3.39 consensus view. Operating revenue growth of 6.2% was in line with our 6%-10% forecast, amid 5.3% earned premium growth, 13% higher net investment income, and 7.9% fee revenue growth. Q1 written premium growth of 4% and full-year 2025 growth of 7% bode well for 2026 revenue trends as premiums are earned. Underwriting results improved significantly, with Personal Lines combined ratio improving to 87.7% from 106.1% and underlying combined ratio to 85.0% from 89.7%. Business Insurance combined ratio was stable at 94.8%. Weighing the Q1 EPS miss with HIG's decent top-line growth and discounted valuation to peers, we view the shares as undervalued.

$HIG
Research

Research Alert: CFRA Keeps Strong Buy Opinion On Shares Of Baker Hughes

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month target price by $14 to $82, reflecting a combination of our sum-of-the-parts (SOTP) and DCF models. For our SOTP model, we presume the oilfield services business (about 50% of BKR's franchise) to be valued at about 10x projected 2027 EBITDA (in line with major peers) and its industrial energy technology business (the other 50%) valued at 14x projected 2027 EBITDA (in line with the peer median). This blended approach, yielding a 12x multiple, implies a value of $73 per share. Meanwhile, our DCF model, using medium-term free cash flow growth of 5% per year, terminal growth of 2.5%, discounted at a WACC of 6.3%, yields intrinsic value of $91 per share. We cut our 2026 EPS estimate by $0.47 to $2.48, but we raise 2027's by $0.07 to $3.24. We acknowledge that the oilfield services business is likely to struggle in 2026 owing to the U.S.-Iran conflict, but the IET business appears quite robust and likely to be a source of both accelerating revenue growth and margins.

$BKR
Research

Research Alert: CFRA Maintains Hold Opinion In Shares Of Wab

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lift our 12-month target to $285 from $275 following WAB's Q1 earnings print, valuing shares at 24.2x our 2027 EPS outlook of $11.76 (revised from $11.46; 2026 EPS estimate up to $10.57 from $10.50), a slight premium to WAB's long-term historical multiple average given structural improvements in earnings quality. While we are cautious on signs of overcapacity in the freight market, an elevated order backlog (12-month sits at over $9 billion), internal initiatives to shore up margins, and potential synergies from M&A activity positions WAB to continue growing earnings at double-digit rates in 2026-2027, in our view. Despite tariff-related cost pressures, WAB has done a commendable job of defending margins via a mix of pricing, lean manufacturing, and pruning of lower-profit operations. Q1 results were mixed but overall positive, in our view. We maintain our Hold recommendation on shares.

$WAB